A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells

Antibody-drug conjugates (ADCs) have evolved as a new class of potent cancer therapeutics. We here report on the development of ADCs with specificity for the B-cell lineage specific (surface) antigen CD22 being expressed in the majority of hematological malignancies. As targeting moiety a previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Tobias, Mavratzas, Athanasios, Kiesgen, Stefan, Haase, Stephanie, Bötticher, Benedikt, Exner, Evelyn, Mier, Walter, Grosse-Hovest, Ludger, Jäger, Dirk, Arndt, Michaela A. E., Krauss, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641194/
https://www.ncbi.nlm.nih.gov/pubmed/26605343
http://dx.doi.org/10.1155/2015/561814

Ejemplares similares

Ejemplares similares